share_log

MilkLab Shrinks Its Annual Loss

MilkLab Shrinks Its Annual Loss

MilkLab 缩减了年度亏损
sharecafe ·  2023/08/29 03:43

Noumi (ASX:NOU), the company behind MilkLab and a range of plant-based dairy products, formerly known as Freedom Foods, has shown promising progress with a sharp reduction in its annual loss for the year ending June 30.

纽米(澳大利亚证券交易所股票代码:NOU)是MilkLab和一系列植物性乳制品(前身为Freedom Foods)的幕后推手,该公司在截至6月30日的一年中大幅减少了年度亏损,取得了可喜的进展。

The company reported a loss of $46.9 million, reflecting the ongoing success of its turnaround strategy, implemented after a near-collapse situation two years prior. This loss represents just a quarter of the staggering $161 million deficit from the previous year.

该公司报告亏损4690万美元,反映出其扭亏为盈战略的持续成功,该战略在两年前濒临崩溃后实施。这一亏损仅占前一年1.61亿美元惊人赤字的四分之一。

Annual revenue saw a noteworthy uptick of 5.6%, reaching nearly $552 million, driven by growing consumer interest in its dairy and nutritional offerings, particularly the MilkLab line of almond milk.

由于消费者对其乳制品和营养产品的兴趣日益浓厚,尤其是MilkLab系列杏仁奶,年收入显著增长5.6%,达到近5.52亿美元。

This shift was mirrored in the company's adjusted operating EBITDA, a non-traditional measure of profit, which surged to $30.4 million for the fiscal year 2022-23, compared to a modest $7 million in the preceding year.

这一转变反映在该公司调整后的营业EBITDA中,这是一种非传统的利润衡量指标,在2022-23财年飙升至3,040万美元,而上一财年仅为700万美元。

The reported net loss incorporates non-cash impairments totaling $8.2 million related to the valuation of plant and equipment in the Dairy and Nutritionals segment, as well as $39.5 million in adjustments to the fair value of convertible notes.

报告的净亏损包括与乳制品和营养部门厂房和设备估值相关的总计820万美元的非现金减值,以及3950万美元的可转换票据公允价值调整。

Directors clarified, "Excluding these non-cash items, the Company reported a positive net profit after tax of approximately $0.8 million, compared to a loss of $80.3 million in FY22."

董事们澄清说:“不包括这些非现金项目,公司报告的税后净利润约为80万美元,而22财年为亏损8030万美元。”

Directors attributed the 10.8% revenue growth of the Consumer Nutritionals portfolio to investments in brands like Vital Strength and the development of new products.

董事们将Consumer Nutritionals投资组合10.8%的收入增长归因于对生力军等品牌的投资和新产品的开发。

The company maintained a slight increase in cash at bank and undrawn facilities, amounting to $36.6 million, ensuring sufficient liquidity for day-to-day operations in line with current market conditions and expectations.

该公司在银行的现金和未提取贷款略有增加,总额为3660万美元,确保了符合当前市场状况和预期的日常运营有足够的流动性。

CEO Michael Perich expressed in an ASX filing, "The past year marked significant progress for Noumi as we advanced through our three-phase Reset, Transform, and Grow strategy in the face of occasional headwinds. Our focus on executing our plan has yielded tangible accomplishments on the path to sustainable, long-term growth."

首席执行官迈克尔·佩里奇在提交给澳大利亚证券交易所的一份文件中表示:“过去一年,随着我们在偶尔遇到逆风的情况下,通过三个阶段的重置、转型和增长战略向前推进,努米取得了重大进展。我们专注于执行我们的计划,在实现可持续、长期增长的道路上取得了切实的成就。”

Perich continued, "In addition to the continuous expansion of our Plant-based Milks business, exemplified by another record earnings performance of our flagship brand, Milklab, we are particularly pleased with the substantial turnaround in Dairy and Nutritionals."

佩里奇接着说:“除了我们的植物奶业务不断扩大之外,我们的旗舰品牌牛奶实验室的另一个创纪录的盈利表现也证明了这一点,我们对乳制品和营养领域的大幅好转感到特别高兴。”

He noted, "Dairy and Nutritionals, which recorded an operating loss in FY22, achieved positive adjusted operating EBITDA in the latter half of FY23, representing a significant stride towards long-term sustainability."

他指出,“在22财年录得营业亏损的乳品和营养品,在23财年下半年实现了调整后的营业EBITDA正数,标志着朝着长期可持续性迈出了重要的一步。”

Perich concluded, "Looking ahead, our priorities include enhancing distribution for the Plant-based Milks business both domestically and internationally, and solidifying the recovery in Dairy and Nutritionals. Despite challenges posed by the ongoing dislocation of the Australian farmgate milk price from global prices, we remain committed to adapting to the market's demands."

佩里奇总结说:“展望未来,我们的首要任务包括加强植物奶业务在国内和国际上的分销,巩固乳制品和营养品的复苏。尽管澳大利亚农场牛奶价格持续与全球价格脱节带来了挑战,但我们仍致力于适应市场的需求。”

1x1.png?futu_img_keep_extra_domain=1

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发